ALT

Altimmune Inc

Exchange: NASDAQSector: HealthcareIndustry: Biotechnology

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH.

Did you know?

Currently operating at a negative 244702.8% profit margin.

Current Price

$2.82

+8.46%

GoodMoat Value

$0.00

99.9% overvalued

Profile

Valuation (TTM)

Market Cap$294.00M

P/E-3.34

EV—

P/B1.31

Shares Out104.25M

P/Sales8166.58

Revenue$36000.00

EV/EBITDA—

Altimmune Inc (ALT) Valuation

ALT Fair Value Estimate

$0.0099.9% overvalued

Blended fair value estimate based on DCF, Graham Number, and earnings-based models.

ALT Valuation Metrics

FCF$-67.55M

FCF Growth Rate—

EPS Growth (CAGR)—

WACC10.00%

Fair Value Models

Graham Number, PEG-based, and Earnings-based models

View Fair Value →

ALT Valuation & Fair Value Analysis

Altimmune Inc (ALT) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.

The GoodMoat Fair Value target for Altimmune Inc is $0.00. The current stock price is $2.82, suggesting the stock is 162817.4% overvalued.

The price-to-earnings (P/E) ratio is -3.34. Price-to-book ratio is 1.31. Price-to-sales ratio is 8166.58. PEG ratio is 0.16.

GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of Altimmune Inc's intrinsic value.